JUNE 2022

Social Bond Impact Report

ROYALTY PHARMA

TABLE OF CONTENTS



References to "Royalty Pharma," the "Company," "we," "us," or "our" and similar expressions refer to Royalty Pharma plc and its subsidiaries. Royalty Pharma plc is externally managed and does not employ its own personnel, but instead depends upon RP Management, LLC, a Delaware limited liability company, and its executive officers and employees for virtually all of the services it requires. References to an "employee" or "employees" and such similar expressions refer to such person's or persons' role at RP Management, LLC, unless the context of a particular reference requires otherwise.

OVERVIEW OF ROYALTY PHARMA

By the numbers

$18+ billion
capital deployed since 2012

$10-12 billion
capital deployment target over the next five years to fund biopharma innovation

60%+
of therapies in our portfolio address diseases on the Access to Medicines list

$600 million
social bond issued in 2021

$62 million
in pledges and contributions to nonprofit institutions by Royalty Pharma and management (2020-May 2022)

We enable institutions and companies on the forefront of discovering lifesaving therapies to improve human health with our full suite of funding solutions.

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry.

Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions and non-profits through small- and mid-cap biotechnology companies to leading global pharmaceutical companies.

Our portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's Trodelvy, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, Johnson & Johnson's Tremfya, and ten development-stage product candidates. The products in our portfolio address therapeutic areas such as rare diseases, cancer, neurology, immunology, hematology and diabetes.



Principles

INTEGRITY
Maintain the highest ethical standards and trust in our role as investors and partners to the life sciences industry

CULTURE
Build a diverse, talented and inclusive workforce that will deliver competitive advantage and help us execute our strategy and drive our business forward

RESPONSIBILITY
Positively impact communities and support the work of patient advocacy groups and medical research foundations

Accelerating life sciences innovation to deliver for partners, patients and society

We fund innovation in the biopharmaceutical industry both directly and indirectly — directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.

We believe that our significant scale, flexible business model and extensive expertise uniquely position us to accelerate innovation in the biopharmaceutical industry. We seek to create favorable outcomes for all parties and play an important role in providing capital to the biopharmaceutical ecosystem that supports innovation and positively impacts human health.

Our sustainability efforts reflect the uniqueness of our business model. We do not directly conduct research, manufacture or market products. However, we seek to promote responsible practices through our investment process, partner selection and due diligence practices. By customizing our approach to environmental, social and governance ("ESG") topics in our investment process, we can reduce risk and drive impact, and we strive to invest in novel therapies that address unmet patient needs and support ethical business practices.



ROYALTY PHARMA'S $600 MILLION INAUGURAL SOCIAL BOND

Second Party Opinion

In 2021, we introduced our Social Bond Framework, available on our website.

ISS, our Second Party Opinion provider, noted that Royalty Pharma "contributes significantly to the development of new prescription drugs and therapies, which are assessed positively for the sustainable development goal of ensuring health." ISS determined our Framework to have a Significant Contribution to SDG 3.

Issuance Details

Issuer	Royalty Pharma plc
Issue Date	July 26, 2021
Maturity Date	September 2, 2031
Principal Amount	$600.0 million
Net Proceeds	$586.9 million
Coupon	2.15%
CUSIP	78081BAN3

On July 26, 2021, Royalty Pharma plc issued its inaugural social bond consisting of $600 million fixed-rate 10-year notes. The bond is the first issued under our Social Bond Framework, which aims to advance our broader ESG initiatives as we seek to accelerate life sciences innovation and the development of lifesaving therapies and treatments.

Eligible Investments are expected to contribute to SDG 3 ("Good Health and Well Being") and SDG 9.5 ("Enhance Scientific Research, Encourage Innovation"). Building on our commitment to diversity, equity and inclusion, the co-managers for the bond included Minority and Women-Owned Business Enterprise and Service-Disabled Veteran-Owned Business firms.

Social Bond Framework Overview

Use of Proceeds	An amount equal to the net proceeds from the sale of any Social Bond issuances will finance and/or refinance, in whole or in part, one or more new or existing Eligible Investments. "Eligible Investments" include investments made by Royalty Pharma or any of its subsidiaries and affiliates beginning with the issuance date of any Social Bonds, or in the 24 months prior to any such issuance. Eligible investments will aim to fund innovation in the biopharmaceutical industry, and eligibility criteria are detailed in Royalty Pharma's Social Bond Framework.
Investment Evaluation and Selection	Selected members from the Treasury, Research & Investments and Legal teams will review and select investments that align with our Social Bond Framework. Final allocation will be reviewed and approved by the Treasurer.
Management of Proceeds	Royalty Pharma has established an internal process to track the allocation and use of any Social Bond proceeds, and to ensure that an amount equal to the net proceeds from any Social Bond is allocated to Eligible Investments. Pending allocation, proceeds may be temporarily invested in cash, cash equivalents and/or held in accordance with Royalty Pharma's internal cash management policies. The Company will aim to allocate investments as soon as practicable.
Reporting and External Review	On an annual basis until all proceeds of any Social Bond have been fully allocated, and on a timely basis in the case of material developments, Royalty Pharma will publish a Social Bond Impact Report. The report will detail the amount of net proceeds allocated to each Eligible Investment, either individually or by category, along with a brief investment description and expected impact metrics, where feasible. The report will be accompanied by assertions from management and an independent third-party examination of these assertions.

2021 SOCIAL BOND IMPACT

$587 million

TOTAL ALLOCATION

100% allocated as of June 30, 2022

26% New investments, 74% Existing investments*

49% Indirect investments (acquisition from original innovators), 51% Direct investments via biopharma partnerships

ACQUISITION OF ROYALTIES FROM ORIGINAL INNOVATORS

trikafta® CYSTIC FIBROSIS FOUNDATION®

$212 million

October 2020

Acquisition of residual royalty interest in Vertex's **cystic fibrosis ("CF") franchise** of drugs enables the Cystic Fibrosis Foundation to continue its research and development of life-saving therapies and support for patients with CF, an orphan disease

Entyvio® vedolizumab | Massachusetts General Hospital Founding Member, Mass General Brigham

$75 million

February 2020

Acquisition of **Entyvio** provided capital for Massachusetts General Hospital to accelerate its investment in science and discovery for benefit of patients worldwide, including in underserved diseases

DIRECT INVESTMENTS VIA BIOPHARMA PARTNERSHIPS

Cytokinetics

$75 million

January 2022 / March 2022

Direct investment in Cytokinetics to fund investment and potential launch of **aficamten** and address unmet needs in hypertrophic cardiomyopathy

bioCryst®

$75 million

BCX9930 / November 2021

$75 million

orladeyo® / December 2020

Direct investment in BioCryst to accelerate the launch and development of treatments for rare disorders, including the launch of **Orladeyo** to treat hereditary angioedema and investment in development-stage product candidate **BCX9930**

biohaven pharmaceuticals

$75 million

August 2020 / March 2021

Direct investment in Biohaven to fund the development of **zavegepant**, a next-generation therapy for patients suffering from the debilitating effects of migraine disease

**Investments are considered "new" if acquired subsequent to the July 26, 2021 issue date of the 2021 social bond*

INVESTMENT HIGHLIGHTS

Cystic Fibrosis Foundation's Residual Royalty Interest in Vertex's CF Franchise

$212 MILLION

October 2020

HOW WE DELIVER IMPACT

Investment funds R&D for new treatments for CF, an orphan disease

Original innovator: Cystic Fibrosis Foundation

Target Population: 80,000+ patients worldwide with CF

Source: Cystic Fibrosis Foundation; Royalty Pharma press release dated November 2, 2020

In October 2020, Royalty Pharma acquired the Cystic Fibrosis Foundation's residual royalty interest in Vertex's franchise of CF products for an upfront payment of $575 million and a potential milestone payment of $75 million. CF is a fatal genetic disease that primarily affects the lungs and digestive system. **An estimated 80,000+ children and adults worldwide are living with CF and over 1,000 new patients are diagnosed each year in the United States.** CF is an orphan disease, which is defined by the Orphan Drug Act as a disease or condition that affects less than 200,000 people in the United States.

The Cystic Fibrosis Foundation (the "Foundation") is a 501(c)(3) not-for-profit foundation that funds innovative, groundbreaking CF research and provides care and support for patients with CF and their families. The Foundation was founded in 1955 by a group of parents searching for a cure for their children, and in 1989, Foundation-sponsored scientists identified the gene that is defective in patients with CF. This breakthrough paved the way for the discovery of Kalydeco and subsequent combination products Orkambi, Symdeko and Trikafta, which were specifically engineered to treat the underlying cause of CF.

The liquidity provided by our October 2020 royalty acquisition enabled the Foundation to expand its efforts to develop new lifesaving therapies and ensure that the best possible care and patient programs are available for patients with CF and their families. In 2020 alone, the Foundation provided $258 million of funding for CF research and care, the most at any time in its history. The Foundation's top research priorities in 2020 included progressing treatments for the underlying cause of disease for all people with CF, addressing the manifestations of CF and understanding the impact of highly effective modulators.

Our goal in pursuing this agreement...is to maximize the funds available to fuel our mission. With these resources, we are better positioned to address the challenges that people with CF and their families continue to face today and move faster and further down the path to a cure.

MICHAEL BOYLE, MD
President and CEO, Cystic Fibrosis Foundation, November 2, 2020

Entyvio

$75 MILLION

February 2020

HOW WE DELIVER IMPACT

Investment funds continued R&D and innovation at MGH as it seeks to improve patient lives across the globe, including research in diseases underserved by treatment options

Original innovator: MGH

Target Population: General population

Source: Mass General Research Institute; Royalty Pharma press release dated March 5, 2020

In February 2020, Royalty Pharma acquired a royalty interest in Entyvio for $94 million from Massachusetts General Hospital ("MGH"). Entyvio is a monoclonal antibody that is used in the treatment of ulcerative colitis and Crohn's disease, two of the most common forms of inflammatory bowel disease, and is marketed by Takeda.

Entyvio is based on a cell line developed in an MGH lab, and **the proceeds from Royalty Pharma's acquisition of MGH's royalty interest provided capital for it to continue investing in groundbreaking scientific research.** MGH is home to the largest hospital-based research enterprise in the United States, with an annual budget of over nearly $1.2 billion in 2021 and 1.3 million square feet of research space in Boston. **Its diverse research portfolio spans the entire spectrum of biomedical research and plays a crucial role in MGH's efforts to prevent disease, reduce healthcare costs, support communities, train the next generation of scientists and improve the lives of patients across the globe.**

The work and dedication of the MGH inventor team... is reflective of a system-wide commitment to improving care for patients dealing with challenging conditions. Through this transaction with Royalty Pharma, we'll be able to accelerate our investment in discovery and science for the benefit of patients worldwide.

CHRIS COBURN
Chief Innovation Officer, Mass General Brigham, March 5, 2020



Aficamten

$75 MILLION

January 2022 / March 2022

HOW WE DELIVER IMPACT

Supports development of innovative new therapy to address the underlying cause of HCM, a leading cause of sudden cardiac death in young people

Biopharma partner: Cytokinetics

Target population: ~1 in every 500 people (HCM disease prevalence)

Source: Cytokinetics; Royalty Pharma press release dated January 7, 2022

In January 2022, Royalty Pharma invested $50 million upfront to acquire a royalty on Cytokinetic's aficamten, an investigational selective, small molecule oral cardiac myosin inhibitor that is under investigation for hypertrophic cardiomyopathy ("HCM") and was granted Breakthrough Therapy Designation by the Food and Drug Administration ("FDA"). In March 2022, Royalty Pharma funded an additional $50 million under this collaboration upon initiation of Cytokinetics' Phase 3 clinical trial in obstructive HCM in February 2022.

HCM is a rare, complex type of heart disease that affects the heart muscle, and is a leading cause of sudden cardiac death in young people. **HCM affects approximately 1 in 500 individuals worldwide**, and the current standard of care is generic, broad mechanism drugs that are not specific to HCM. Aficamten addresses the underlying cause of HCM to allow the heart to pump more effectively. **Royalty Pharma's investment enabled Cytokinetics to accelerate development of this therapy for patients currently underserved by treatment options.**

With the proceeds from Royalty Pharma's investment, Cytokinetics aims to accelerate its research and development efforts, with the goal of addressing multiple unmet medical needs in cardiovascular diseases and accelerating patient access to lifesaving medicines.



BCX9930

$75 MILLION

November 2021

HOW WE DELIVER IMPACT

Investment funds development of BCX9930 for treatment of PNH, a rare disease underserved by treatment options

Biopharma partner: BioCryst

Target population: ~ 400-500 new patients diagnosed with PNH each year in the United States

In November 2021, Royalty Pharma expanded its partnership with BioCryst and invested $150 million upfront to advance the development of BCX9930, a development-stage oral Factor D inhibitor, into clinical trials across multiple indications. BCX9930 will address unmet needs for patients with paroxysmal nocturnal hemoglobinuria ("PNH").

PNH is a rare acquired, life-threatening disease of the blood. The disease is characterized by destruction of red blood cells, blood clots and impaired bone marrow function, and it is most often diagnosed around 30-40 years of age. **Experts estimate that between 400-500 new cases are diagnosed in the United States each year.**

Through its ongoing clinical trials, BioCryst aims to address unmet needs for patients with PNH, including significant increases in hemoglobin, reduced transfusions, and reductions in key laboratory biomarkers. **The partnership with Royalty Pharma enabled BioCryst to rapidly expand the development of BCX9930 and another earlier stage Factor D inhibitor and improve the lives of patients with PNH and multiple other complement-mediated diseases.**

Orladeyo

$75 MILLION

December 2020

HOW WE DELIVER IMPACT

Supports global commercial launch of Orladeyo, a differentiated new treatment option for HAE, a rare disease underserved by treatment options

Biopharma partner: BioCryst

Target population: 1 in 50,000 to 1 in 150,000 individuals worldwide (HAE disease prevalence)

In December 2020, Royalty Pharma acquired a royalty on Orladeyo, approved by the FDA in December 2020 for the treatment of hereditary angioedema ("HAE"), for an upfront payment of $125 million. **The funds from Royalty Pharma's partnership helped BioCryst fully invest in the launch of Orladeyo and enabled patient access to this transformative new therapy as it launched globally.**

HAE is a rare inherited disorder characterized by recurrent episodes of the accumulation of fluids outside of the blood vessels that causes rapid swelling in the body. **An estimated one in 50,000 to 150,000 individuals is affected by this disorder worldwide.** It is a chronic disease, and individuals are always at risk of an attack. Until now, preventative therapy options have been limited to intravenous infusions, subcutaneous injections or androgens. Orladeyo is the first and only oral therapy designed specifically to prevent HAE attacks. Since Royalty Pharma's December 2020 investment, BioCryst has launched Orladeyo in the United States and globally in Denmark, France, Germany, Japan, the United Kingdom and other countries.

BioCryst has reported that most patients are well-controlled on Orladeyo and remain on therapy, and that Orladeyo is transforming the lives of HAE patients and on a trajectory to become the market-leading prophylactic therapy.

Source: Biocryst; Royalty Pharma press releases dated December 7, 2020 and November 22, 2021; National Organization for Rare Disorders, Inc.; Aplastic Anemia and MDS International Foundation

Zavegepant

$75 MILLION

August 2020, March 2021

HOW WE DELIVER IMPACT

Fund development of new, intranasal therapy to deliver ultra-rapid relief to patients suffering from migraine, a debilitating disease underserved by adequate treatment options for patients

Biopharma partner: Biohaven

Target population: ~40 million people in the United States suffering from migraine



Source: Biohaven; Royalty Pharma press release dated August 7, 2020

In August 2020, Royalty Pharma expanded its ongoing partnership with Biohaven to advance its calcitonin gene-related peptide ("CGRP") receptor antagonist program through the development of zavegepant for the treatment of migraine. Royalty Pharma provided Biohaven with an upfront payment of $150 million at closing and subsequently funded an additional $100 million in March 2021 upon the start of the oral zavegepant Phase 3 program.

Migraine is the second most debilitating disease worldwide and impacts all aspects of a person's life, causing significant emotional and physical distress. **Nearly 40 million people suffer from migraine disease**, and it disproportionately affects women and people of color. Biohaven is already impacting patient lives with Nurtec ODT, its oral CGRP antagonist that is approved for preventive and acute treatment of migraine, which has achieved two million prescriptions as of May 2022. **Biohaven's expanded partnership with Royalty Pharma allowed it to further invest in next-generation therapies to treat this debilitating disease as it continues addressing the unmet needs of the migraine community.**

Zavegepant is a small molecule CGRP receptor antagonist in Phase 3 clinical development for the acute treatment and prevention of migraines. Biohaven will use these proceeds to fund zavegepant's development in migraine and non-migraine indications. In exchange for these funds, Royalty Pharma will obtain a royalty on worldwide sales of zavegepant and certain success-based milestones.

Zavegepant is the first and only intranasal CGRP receptor antagonist in late stage development. Its unique intranasal delivery offers the potential for rapid onset of action, and it would provide a new treatment option for patients with nausea or vomiting that need a non-oral, ultra-rapid treatment option. Biohaven reported positive topline results from its pivotal migraine trial of intranasal zavegepant, demonstrating ultra-rapid pain relief at the earliest measured time point of 15 minutes and sustained efficacy through 48 hours after a single intranasal dose.

Royalty Pharma is an industry leader in funding innovative biopharmaceutical therapies and we are pleased to expand our partnership. This transaction…will allow us to quickly broaden our CGRP receptor antagonist franchise into migraine adjacencies, non-migraine indications and new formulations across the globe.

VLAD CORIC, MD
Chief Executive Officer, Biohaven, August 7, 2020

MANAGEMENT'S ASSERTION

June 30, 2022

We, as members of management of Royalty Pharma plc (the "Company"), are responsible for whether the amount equal to net proceeds from the July 26, 2021 issuance of 2.150% Notes due September 2, 2031 issued by Royalty Pharma plc was fully allocated, during the period from July 26, 2021 to June 30, 2022 (the "Reporting Period") to qualifying Eligible Investments made during the period from July 26, 2019 to June 30, 2022 that meet one or more of the Eligibility Criteria (as defined in the "Use of Proceeds" section of the Prospectus Supplement dated July 15, 2021, to the Prospectus dated July 14, 2021 filed by the Company on July 19, 2021, with the Securities and Exchange Commission pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended). The Eligibility Criteria are also set forth in Table 1 below. Management of Royalty Pharma plc is also responsible for the assertion, selection of the Eligibility Criteria and the allocation, during the Reporting Period, of amounts to Eligible Investments that meet one or more of the Eligibility Criteria.

We have obtained a Second Party Opinion from an outside party, a provider of ESG and corporate governance research and ratings to investors, concluding that the Eligible Investments are in compliance with the Social Bond Principles dated June 2021, published by the International Capital Market Association.

We assert that the amount equal to net proceeds from the July 26, 2021 issuance of 2.150% Notes due September 2, 2031 issued by Royalty Pharma plc was fully allocated, during the Reporting Period, to qualifying Eligible Investments made during the period from July 26, 2019 to June 30, 2022 that meet one or more of the Eligibility Criteria.

Table 1

Eligible Social Investment category	Eligibility Criteria for Social Bond Proceeds
Access to essential services: Healthcare	Social Bond Proceeds may be used for investments related to partnerships that fund innovation in the biopharmaceutical industry intended to treat diseases such as: • Orphan diseases, as defined by the FDA; • Top diseases or leading causes of death, as defined by the World Health Organization and/or United Nations; or • Diseases that are underserved by research and treatment options These investments are made either: • Directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, or; • Indirectly when we acquire existing royalties from the original innovators, including from hospitals, not-for-profit foundations, and academic institutions

Note 1: Diseases that are underserved by research and treatment options may include diseases that appear in the Rare Disease Database maintained by the National Organization for Rare Disorders, Inc.; diseases for which current approved therapies do not provide adequate relief nor reduce the disease burden for patients; diseases that appear in the 2022 Access to Medicines Index; fatal diseases for which there is currently no cure; and diseases that have been granted Breakthrough Therapy Designation by the FDA, among other factors.

Management of Royalty Pharma plc

Ernst & Young LLP
One Manhattan West
New York, NY 10001

Tel: +1 212 773 3000
Fax: + 1 212 773 6350
ey.com

Report of Independent Accountants

To the Management of Royalty Pharma plc:

We have examined management's assertion, included in the accompanying report, Management's Assertion, that the amount equal to net proceeds from the July 26, 2021 issuance of 2.150% Notes due September 2, 2031 issued by Royalty Pharma plc (the "Company") was fully allocated, during the period from July 26, 2021 through June 30, 2022 (the "Reporting Period"), to qualifying Eligible Investments made during the period from July 26, 2019 to June 30, 2022 that meet one or more of the Eligibility Criteria (as defined in the "Use of Proceeds" section of the Prospectus Supplement dated July 15, 2021, to the Prospectus dated July 14, 2021 filed by the Company on July 19, 2021, with the Securities and Exchange Commission pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended). Royalty Pharma plc's management is responsible for the assertion, having a reasonable basis for its assertion, selection of the Eligibility Criteria and the allocation, during the Reporting Period, of amounts to Eligible Investments that meet one or more of the Eligibility Criteria. Our responsibility is to express an opinion on the assertion based on our examination.

Our examination was conducted in accordance with attestation standards established by the American Institute of Certified Public Accountants ("AICPA"). Those standards require that we plan and perform the examination to obtain reasonable assurance about whether management's assertion is fairly stated, in all material respects. An examination involves performing procedures to obtain evidence about management's assertion. The nature, timing, and extent of the procedures selected depend on our judgment, including an assessment of the risks of material misstatement of management's assertion, whether due to fraud or error. We believe that the evidence we obtained is sufficient and appropriate to provide a reasonable basis for our opinion.

We are required to be independent of Royalty Pharma plc and to meet our other ethical responsibilities, as applicable for examination engagements set forth in the Preface: Applicable to All Members and Part 1 – Members in Public Practice of the Code of Professional Conduct established by the AICPA.

Our examination was not conducted for the purpose of evaluating (i) whether funds in excess of the net proceeds were allocated to Eligible Investments during the Reporting Period, (ii) the amount allocated to each category of Eligible Investments during the Reporting Period, (iii) the social benefits of the Eligible Investments, (iv) conformance of any Eligible Investments with any third-party published principles, standards or frameworks, such as the Social Bond Principles, dated June 2021, published by the International Capital Market Association or (v) any information included in the Company's report or on the Company's website, other than management's assertion. Accordingly, we do not express an opinion or any other form of assurance other than on management's assertion included in Management's Assertion.

In our opinion, management's assertion, included in Management's Assertion, that the amount equal to net proceeds from its July 26, 2021 issuance of 2.150% Notes due September 2, 2031 was fully allocated during the Reporting Period to qualifying Eligible Investments that met one or more of the Eligibility Criteria, is fairly stated, in all material respects.

Ernst & Young LLP

June 30, 2022

ROYALTY PHARMA

www.royaltypharma.com

Disclaimer: This report is not, does not contain and is not intended as an offer to sell or a solicitation of any offer to buy any securities issued by Royalty Pharma. No representation is made as to the suitability of any issuance of social bonds to fulfill environmental, social and sustainability criteria required by prospective investors. Eligible Investments may not satisfy an investor's expectations concerning environmental, social or sustainability benefits, and may result in adverse impacts. The information contained herein is provided as of the date of this report, and Royalty Pharma does not undertake to update any of such information.